Cellectar Biosciences, Inc. Resources

News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • CLR 131
  • Clinical Trials
    • Overview
    • Relapsed or Refractory Multiple Myeloma Clinical Trial Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Trial Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Trial Recruiting
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603

Oct 4, 2016

Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma

Sep 29, 2016

Cellectar Biosciences To Present at OktoberINVESTfest

Sep 21, 2016

Cellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference

Sep 19, 2016

Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant

Sep 12, 2016

Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference

Sep 6, 2016

UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results

Aug 12, 2016

Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results

Aug 11, 2016

Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance

Aug 8, 2016

Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study

Aug 3, 2016
    • 1...
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • ...23
    © 2019 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A